Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price dropped 10.2% during mid-day trading on Thursday . The stock traded as low as GBX 10.87 and last traded at GBX 10.87. Approximately 254,658 shares traded hands during mid-day trading, a decline of 2% from the average daily volume of 259,632 shares. The stock had previously closed at GBX 12.10.
Allergy Therapeutics Price Performance
The stock’s 50-day simple moving average is GBX 10.49 and its two-hundred day simple moving average is GBX 9.01. The firm has a market cap of £743.11 million, a P/E ratio of -14.40, a PEG ratio of -30.70 and a beta of 1.40. The company has a debt-to-equity ratio of 835.48, a current ratio of 1.63 and a quick ratio of 1.48.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Featured Articles
- Five stocks we like better than Allergy Therapeutics
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
